Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use? (Q38212485)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24837511 AND SRC:MED&resulttype=core&format=json

18 March 2020

title

Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24837511 AND SRC:MED&resulttype=core&format=json

18 March 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24837511 AND SRC:MED&resulttype=core&format=json

18 March 2020

author name string

Marius M Strioga

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24837511 AND SRC:MED&resulttype=core&format=json

18 March 2020

Vita Pasukoniene

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24837511 AND SRC:MED&resulttype=core&format=json

18 March 2020

Agata Mlynska

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24837511 AND SRC:MED&resulttype=core&format=json

18 March 2020

Valerijus Ostapenko

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24837511 AND SRC:MED&resulttype=core&format=json

18 March 2020

Virgil Schijns

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24837511 AND SRC:MED&resulttype=core&format=json

18 March 2020

language of work or name

English

0 references

publication date

14 May 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24837511 AND SRC:MED&resulttype=core&format=json

18 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24837511 AND SRC:MED&resulttype=core&format=json

18 March 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24837511 AND SRC:MED&resulttype=core&format=json

18 March 2020

issue

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24837511 AND SRC:MED&resulttype=core&format=json

18 March 2020

page(s)

4015-4024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24837511 AND SRC:MED&resulttype=core&format=json

Immuno-oncology: understanding the function and dysfunction of the immune system in cancer

18 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Mucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of mucosal tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Higher numbers of T-bet( ) intratumoral lymphoid cells correlate with better survival in gastric cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

The immune contexture in human tumours: impact on clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Therapeutic efficacy of antitumor dendritic cell vaccinations correlates with persistent Th1 responses, high intratumor CD8 T cell recruitment and low relative regulatory T cell infiltration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

The three Es of cancer immunoediting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Cellular constituents of immune escape within the tumor microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Cancer despite immunosurveillance: immunoselection and immunosubversion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Inhibition of Granzyme B by PI‐9 protects prostate cancer cells from apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Dendritic cells and their role in tumor immunosurveillance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Therapeutic dendritic cell-based cancer vaccines: the state of the art.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

A listing of human tumor antigens recognized by T cells: March 2004 update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

The response of autologous T cells to a human melanoma is dominated by mutated neoantigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Unique human tumor antigens: immunobiology and use in clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Translating tumor antigens into cancer vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Regulation of the immune response by antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Tumour markers: An overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Comparative Analysis of the In Vivo Expression of Tyrosinase, MART-1/Melan-A, and gp100 in Metastatic Melanoma Lesions: Implications for Immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Survivin, a cancer target with an emerging role in normal adult tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Tumor-Associated Carbohydrate Antigens Defining Tumor Malignancy: Basis for Development of Anti-Cancer Vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Cross-presentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Interplay among viral antigens, cellular pathways and tumor microenvironment in the pathogenesis of EBV-driven lymphomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4( ) T lymphocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Tumor immunity and autoimmunity induced by immunization with homologous DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Dendritic Cell Based Tumor Vaccination in Prostate and Renal Cell Cancer: A Systematic Review and Meta-Analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Tumor evasion from T cell surveillance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Genetic immunization of mice with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

The Drosophila genome sequence: implications for biology and medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Rat-mouse and rat-human comparative maps based on gene homology and high-resolution zoo-FISH

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Xenogeneic human p53 DNA vaccination by electroporation breaks immune tolerance to control murine tumors expressing mouse p53.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Immunotherapy of hepatocellular carcinoma with a vaccine based on xenogeneic homologous alpha fetoprotein in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Generation of an effective anti-tumor immunity after immunization with xenogeneic antigens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Xenogeneic immunization with human tyrosine hydroxylase DNA vaccines suppresses growth of established neuroblastoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Enhancement of DNA vaccine efficacy by targeting the xenogeneic human chorionic gonadotropin, survivin and vascular endothelial growth factor receptor 2 combined tumor antigen to the major histocompatibility complex class II pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Xenogeneic Murine Tyrosinase DNA Vaccine for Malignant Melanoma of the Digit of Dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Recent progress in canine tumor vaccination: potential applications for human tumor vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Dendritic cell targeting of survivin protein in a xenogeneic form elicits strong CD4 T cell immunity to mouse survivin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Antigen-bearing immature dendritic cells induce peptide-specific CD8( ) regulatory T cells in vivo in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Xenovaccinotherapy for colorectal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Immunization with a prostate cancer xenoantigen elicits a xenoantigen epitope-specific T-cell response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Biodistribution of radiolabelled human dendritic cells injected by various routes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Route of Administration Modulates the Induction of Dendritic Cell Vaccine-Induced Antigen-Specific T Cells in Advanced Melanoma Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Intranodal Administration of Peptide-Pulsed Mature Dendritic Cell Vaccines Results in Superior CD8 T-Cell Function in Melanoma Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Improvement of different vaccine delivery systems for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Adoptive transfer of tumor-reactive Melan-A-specific CTL clones in melanoma patients is followed by increased frequencies of additional Melan-A-specific T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.VACCINE.2014.05.006

10.1016/J.VACCINE.2014.05.006

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24837511 AND SRC:MED&resulttype=core&format=json

18 March 2020

1 reference